Last reviewed · How we verify
D-138 (CHOLESTEROL)
At a glance
| Generic name | CHOLESTEROL |
|---|---|
| Sponsor | DNA Labs, Inc. |
| Drug class | Vitamin B12 [EPC] |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Causes and Natural History of Dyslipidemias
- Cardiovascular Evaluation of Patients With High Cholesterol and Normal Volunteers
- Study of Smith-Lemli-Opitz Syndrome
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (PHASE1)
- Using Big Data to Conduct Innovative Cardiovascular Clinical Trials (NA)
- The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease (NA)
- Evaluation of Lipoproteins
- Evaluation of Food Supplementation in Subjects With Suboptimal Levels of LDL Cholesterol (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D-138 CI brief — competitive landscape report
- D-138 updates RSS · CI watch RSS
- DNA Labs, Inc. portfolio CI